Endralazine ― a new hydralazine-like antihypertensive with high systemic bioavailability

Endralazine (E), a new hydralazine-like antihypertensive was given intravenously (0.05 mg/kg) to 10 normal volunteers (5 slow and 5 fast acetylators). Plasma levels were fitted to a 3 compartment model and pharmacokinetic parameters (area under curve [AUC infinity 0], clearance, volume of distributi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1983-01, Vol.25 (4), p.553-556
Main Authors: REECE, P. A, COZAMANIS, I, ZACEST, R
Format: Article
Language:English
Subjects:
Absorption
Acetylation
Adult
Antihypertensive agents
Biological and medical sciences
Biological Availability
Cardiovascular system
Humans
Kinetics
Male
Medical sciences
Pharmacology. Drug treatments
Phenotype
Pyridazines - blood
Pyridazines - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endralazine (E), a new hydralazine-like antihypertensive was given intravenously (0.05 mg/kg) to 10 normal volunteers (5 slow and 5 fast acetylators). Plasma levels were fitted to a 3 compartment model and pharmacokinetic parameters (area under curve [AUC infinity 0], clearance, volume of distribution, half-lives) obtained in the usual way. Bioavailabilities of 5 and 10 mg oral doses of E were determined from the AUC infinity 0 generated in a previous study of oral E given to the same subjects. E had high system bioavailability (73.5-99.1%) suggesting that it was almost completely absorbed without undergoing appreciable first-pass metabolism. Furthermore, dose size and acetylator phenotype did not significantly affect the bioavailability of E. This behavior contrasts with that of hydralazine where systemic bioavailability was less than 40%, and 2 to 3 times higher in slow acetylators than in fast acetylators. It is concluded that the bioavailability of E is high and not influenced by acetylator phenotype; these properties suggest some clinical advantages for the drug.
ISSN:0031-6970
1432-1041
DOI:10.1007/BF00542127